Avsar.

Healthcare · Healthcare Service Provider

Nephrocare Health Services Ltd (NEPHROPLUS)

₹614.55

Mkt cap
₹6,180 Cr
P/E ratio
72.60
P/B
5.54
Div yield
0.00%
ROE
8.83%
ROCE
15.30%
EPS (TTM)
₹8.46
Book value
₹111
52W range
446–782
Sector
Healthcare

Price history

Previous close

Incorporated in 2010, Nephrocare Health Services Ltd. provides end-to-end dialysis care through a wide network of clinics across India and select international markets. [1]

NSE NEPHROPLUSBSE 544647
Health check
Mixed
ValuationExpensive
ProfitabilityAverage
GrowthHigh
TechnicalsNeutral
52-week range
−21.36% from high
₹615
₹446+37.79% from low₹782
Current
₹614.55
Prev close
₹628.55
Day
−2.23%
Price performance
1D
−2.97%
1W
+2.26%
1M
−8.06%
3M
−10.72%
6M
+14.69%
1Y
—
YTD
+29.54%

Financials

Revenue, profit & margin
P/E ratio
72.6×
NEPHROPLUS is 94% above the sector median of 37.4×
NEPHROPLUS72.6×
Sector median37.4×
 Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Trend
Sales197219228246260266282
Expenses153168180182199215221
Operating Profit44514864615160
OPM %22%23%21%26%23%19%21%
Other Income54743127
Interest56645632
Depreciation18192023222625
Profit before tax263029-1363341
Tax %24%17%17%1,427%11%9%22%
Net Profit202524-9323032
EPS in Rs19.3423.9113.10-5.243.213.033.19
Raw PDF

Earnings

Results dates & reactions
Next results
3 Nov '26scheduled

Fresh quarters land in the Financials table above, tagged NSE until screener catches up.

Avg earnings-day move −4.65% · closed higher next day 0 of last 1
 Q1FY27
Broadcast11 Aug '26◦
Earnings day−4.65%
+1 day−5.11%
+5 days−2.99%
+15 days−2.75%
+30 days−0.39%
FilingXBRL

Corporate actions

Last 6 months

No recent corporate actions

Dividends, splits, and bonuses in the last six months show up here.

Results analysis

Shareholding

as of Sep 2026
58.32%Promoter
Promoters58.32%5.53
FIIs11.73%2.95
DIIs8.11%0.94
Public21.85%3.55
Ownership trend

Peers

7 companies
Valuation vs quality
P/E × ROCE · bubble = market cap
NameCMPP/EMkt CapDiv YldNP QtrQtr Profit VarSales QtrQtr Sales VarROCE
Dr Lal Pathlabs₹1,906.4056.9131,9990.73%171+28.02%798+19.10%28.00%
Vijaya Diagnost.₹1,445.7079.4214,8900.14%53+37.60%231+22.83%20.53%
Metropolis Healt₹545.6554.3911,3200.37%57+25.77%450+16.62%17.81%
Thyrocare Tech.₹456.3041.467,2632.05%15−11.56%271+25.07%35.38%
Nephrocare Health Services₹614.5572.616,1800.00%32+34.89%282+23.69%15.34%
Suraksha Diagno.₹316.3546.021,6480.16%13+38.40%88+20.75%17.29%
Krsnaa Diagnost.₹503.7516.521,6340.40%16−19.12%211+19.95%12.71%
Median: 16 Co.₹377.5837.371,0160.07%13+25.77%103+19.10%21.90%

Filings

Annual reports4
Annual Report 2026Annual Report 2025Annual Report 2024Annual Report 2023
Concall transcripts9
TranscriptAug 2026PPTAug 2026RECAug 2026TranscriptMay 2026PPTMay 2026RECMay 2026TranscriptFeb 2026PPTFeb 2026RECFeb 2026
Credit ratings3
Rating update 20 Jun 2025fitchRating update 22 Mar 2024fitchRating update 30 Dec 2022fitch
Announcements5
Announcement under Regulation 30 (LODR)-Memorandum of Understanding /Agreements 27 Oct - Nephrocare subsidiary acquires dialysis center assets in Quezon City, Philippines, under ATA dated October 27, 2026.Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 21 Oct - Q2FY27 earnings call scheduled for November 4, 2026 at 11:00 A.M. IST.Board Meeting Intimation for Consideration And Approval Of The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter And Half Year Ended September 30, 2026. 12 Oct - Board meeting on Nov 3, 2026 to approve Q2 and half-year FY26 results; trading window closed till Nov 5.Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 7 Oct - We are enclosing herewith a certificate under Reg 74(5) of SEBI (DP) Regulations, 2018 for quarter ended 30th September, 2026 received from M/s. KFIN Technologies …Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 28 Sep